Table 5.
Health and economic outcomes of point of care adoption strategies.
| Strategy | Description | Technology | % Viral load volumes tested by platform | Total cost (2019 USD) | Total number suppressed (%) | ICER ($/additional person suppressed) | ||
|---|---|---|---|---|---|---|---|---|
| m-PIMA | Xpert | Centralized | ||||||
| 1 | Status-quo | Centralized | 0% | 0% | 100% | $125,802,848 | 4,382,475 (85·2%) | - |
| 2 | Unsuppressed targeted* | Xpert only | 0% | 34% | 66% | $132,516,289 | 4,548,682 (88·5%) | $40 |
| 2 | Unsuppressed targeted * | m-PIMA only | 27% | 0% | 73% | $132,864,944 | 4,517,130 (87·8%) | dominated |
| 3 | Combination targeted⁎⁎ | Xpert only | 0% | 15% | 85% | $136,218,447 | 4,447,944 (86·5%) | dominated |
| 3 | Combination targeted⁎⁎ | mix | 13% | 2% | 85% | $139,751,552 | 4,447,944 (86·5%) | dominated |
| 3 | Combination targeted⁎⁎ | m-PIMA only | 15% | 0% | 85% | $142,317,674 | 4,400,744 (86·5%) | dominated |
| 4 | All POC | mix | 36% | 64% | 0% | $174,505,308 | 4,857,683 (94·5%) | $136 |
| 4 | All POC | Xpert only | 0% | 100% | 0% | $180,661,135 | 4,857,683 (94·5%) | dominated |
| 4 | All POC | m-PIMA only | 100% | 0% | 0% | $235,769,172 | 4,857,683 (94·5%) | dominated |
⁎
Targeted to facilities with highest number of virally unsuppressed patients.
⁎⁎
Targeted to facilities that have a combination of low viral suppression, long turnaround time and high specimen rejection rates.